References

Type sizer A A

Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiological features. J Clin Neurophysiol. 2001;18:128-147.
Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-119.
Avecillas JF, Golish JA, Giannini C, Yataco JC. Restless legs syndrome: keys to recognition and treatment. Cleve Clin J Med. 2005;72:769-787.
Chaudhuri KR, Forbes A, Grosset D, et al. Diagnosing restless legs syndrome (RLS) in primary care. Curr Med Res Opin. 2004;20:1785-1795.
Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol. 2005;62:591-596.
Hening W, Walters AS, Allen RP, et al. Impact, diagnosis, and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237-246.
MIRAPEX [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2007.
National Institute of Neurological Disorders and Stroke. Restless legs syndrome fact sheet. Available at: http://www.ninds.nih.gov/disorders/restless_legs/
detail_restless_legs.htm?css=print. Accessed January 8, 2008.
The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121-132.
Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 2006;21:1404-1410.
Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67:1034-1039.

Sign Up

Interactive Activities

Try our online activities and interactive quiz to test how much you know about RLS.

IMPORTANT SAFETY INFORMATION ABOUT MIRAPEX: MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

MIRAPEX may cause you to fall asleep without any warning, even while doing normal daily activities, such as driving. When taking MIRAPEX, hallucinations may occur and sometimes you may feel dizzy, sweaty or nauseated upon standing up. The most common side effects in clinical trials for RLS were nausea, headache, and tiredness. You should talk with your doctor if you experience these problems.

Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease and RLS.

This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.

Please see full Prescribing Information, including patient information.